Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations

Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown significantly durable clinical benefits and tolerable toxicities and have improved the survival of patients with various types of cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jun, Zhang, Bicheng, Peng, Ling, Liu, Xiufeng, Sun, Jianguo, Su, Chunxia, Wang, Huijuan, Zhao, Zheng, Si, Lu, Duan, Jianchun, Zhang, Hongmei, Li, Mengxia, Zhu, Bo, Zhang, Li, Li, Jin, Guo, Jun, Luo, Rongcheng, Qiu, Wensheng, Ye, Dingwei, Chu, Qian, Cui, Jiuwei, Dong, Xiaorong, Fan, Yun, Gao, Quanli, Guo, Ye, He, Zhiyong, Li, Wenfeng, Lin, Gen, Liu, Lian, Liu, Yutao, Qin, Haifeng, Ren, Shengxiang, Ren, Xiubao, Wang, Yongsheng, Xue, Junli, Yang, Yunpeng, Yang, Zhenzhou, Yue, Lu, Zhan, Xianbao, Zhang, Junping, Ma, Jun, Qin, Shukui, Wang, Baocheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357053/
https://www.ncbi.nlm.nih.gov/pubmed/37484525
http://dx.doi.org/10.1177/17588359231187205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357053/
https://www.ncbi.nlm.nih.gov/pubmed/37484525
http://dx.doi.org/10.1177/17588359231187205

Ejemplares similares